Centre Antoine Lacassagne
About this institution
Publications Show all
Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib
...Published in Oncoscience
Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder that accounts for 2% of all leukemia. Recent identification of the recurrent V600E BRAF mutation in a majority of HCL patients has led some teams to evaluate the clinical potential of vemurafenib, a BRAF V600 specific inhibitor in a limited number of refractory HCL patients....